Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis - NEJM Publication

The study on intravenous (IV) rehydration for severe acute malnutrition (SAM) with gastroenteritis was published in the *New England Journal of Medicine (NEJM)* and provides critical insights into the management of severely malnourished children with dehydration. Below is a detailed summary of the trial findings and their implications:

### Study Aim:

The trial aimed to evaluate whether IV rehydration improves survival outcomes in children with SAM and gastroenteritis compared to oral rehydration therapy (ORT), challenging the longstanding concerns and restrictions against IV fluids in such cases.

### Background and Concerns:

• According to current World Health Organization (WHO) guidelines, IV fluids are discouraged for children with SAM due to fears of cardiac failure and fluid overload.
• However, these concerns are not strongly evidence-based, and this study sought to rigorously test the efficacy and safety of IV rehydration in this vulnerable population.

### Study Design:

• **Type:** Factorial, open-label, randomized superiority trial.
• **Locations:** Conducted in six hospitals across Uganda, Kenya, Niger, and Nigeria.
• **Participants:** 272 children aged 6 months to 12 years diagnosed with SAM, gastroenteritis, and dehydration.
• **Groups:** Participants were randomized into three groups:

1. **Oral Rehydration:** Received oral rehydration solution (ORS) via nasogastric tubes as needed.

2. **Rapid IV Rehydration:** Received lactated Ringer’s solution (100 mL/kg) over 3–6 hours.

3. **Slow IV Rehydration:** Received lactated Ringer’s solution (100 mL/kg) over 8 hours.

### Primary Outcome:

• Mortality at 96 hours was the primary endpoint.

### Secondary Outcomes:

• 28-day mortality.
• Physiological responses, including electrolyte normalization, weight gain, hydration improvement, and adverse events.

### Key Findings:

1. **Mortality Outcomes:**

• **96-hour mortality:** 8% in the oral group and 7% in the pooled IV groups — no significant survival difference (Relative Risk [RR]: 1.02; 95% CI: 0.41–2.52).
• **28-day mortality:** Similar rates between oral rehydration (12%) and IV rehydration groups (10%) (Hazard Ratio [HR]: 0.85; 95% CI: 0.41–1.78).

2. **Safety Results:**

• No cases of pulmonary edema, heart failure, or fluid overload were observed in any group.
• Serious adverse events occurred in 23% of oral rehydration patients, 21% of rapid IV patients, and 15% of slow IV patients — favoring IV treatment slightly.

3. **Electrolyte Balance:**

• IV rehydration corrected severe hyponatremia faster (subhazard ratio: 1.55; 95% CI: 1.14–2.09).
• Potassium normalization was slower in IV groups compared to oral therapy.

4. **Weight and Hydration Gains:**

• By day 3, children in the IV groups gained slightly more weight (+0.1 kg) than those on oral therapy, but this difference disappeared by day 7.

5. **Nasogastric Tube Use:**

• 93% of oral rehydration patients required nasogastric tubes versus 65% in IV groups, highlighting practical advantages of IV routes in hospitals with limited staffing.

6. **Shock Management:**

• Fewer new cases of shock developed in IV-treated children (5%) compared to oral rehydration patients (9%), indicating better hemodynamic stability.

7. **Baseline Conditions:**

• Over 50% of children had severe hyponatremia or hypokalemia, and 38% presented with altered consciousness — reflecting the severity of illness in the study population.

8. **No Cardiac Compromise:**

• Physiological monitoring confirmed that malnourished children tolerated IV fluids well, countering WHO concerns about cardiac failure or fluid overload.

### Strengths of the Study:

• Strict monitoring, high adherence to protocols, and balanced baseline characteristics enhanced the study's internal validity.
• The trial was conducted across multiple sites in sub-Saharan Africa, ensuring real-world applicability.

### Limitations:

• The overall mortality rate (11%) was lower than expected, reducing the statistical power to detect smaller differences in survival outcomes.
• The study did not compare IV fluids to no rehydration therapy, focusing only on oral versus IV methods.

### Clinical Implications:

• The findings challenge long-held restrictions against IV rehydration for malnourished children with gastroenteritis.
• IV therapy is demonstrated to be safe and effective, potentially simplifying management in hospitals with limited staff where oral feeding is difficult.
• Faster correction of electrolyte imbalances and reduced reliance on nasogastric tubes may make IV rehydration a more practical option in certain clinical settings.

### Core Conclusion:

In severely malnourished children with gastroenteritis, IV rehydration (both rapid and slow methods) is as safe and effective as oral therapy. The study provides robust evidence to reconsider WHO guidelines and supports the use of IV fluids in this vulnerable population.

This landmark trial is expected to influence global clinical practices and guidelines for managing severe acute malnutrition in children.